The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Efficacy of inhaled ciclesonide compared with oral prednisolone in the treatment of asthma exacerbations Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006
Optimum dosing regimen for repeated low dose allergen challenge in chronic allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 103s Year: 2001
Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Monitoring of inflammatory changes in patients with bronchial asthma before and after oral corticosteroid treatment Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Oral corticosteroids in the treatment of exacerbation of severe asthma Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden Year: 2020
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids Source: Breathe 2010; 6: 365 Year: 2010
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Safety of omalizumab therapy in children with allergic asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003
Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
Response of children with bronchial asthma to combined therapy with an oral immunostimulating drug and antileukotrienes Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005
Rescue-free days in patients with mild persistent asthma receiving montelukast sodium or an inhaled corticosteroid Source: Eur Respir J 2002; 20: Suppl. 38, 113s Year: 2002
A comparision of inhaled budesonide and oral prednisolone for children with acute asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003
High or standard initial dose of budesonide to control mild-to-moderate asthma? Source: Eur Respir J 2001; 17: 856-862 Year: 2001
Efficacy of short-term high dose predonisolone therapy in acute exacerbation of bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 71s Year: 2001
Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007
Budesonide/formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroids in patients with mild persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002